Deka Bank Deutsche Girozentrale Uni Qure N.V. Transaction History

Deka Bank Deutsche Girozentrale

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 28, 2022	SELL	$14.54 - $21.5 $43,620 - $64,500	-3,000 Reduced 7.08%	39,400 $704,000
Q4 2021 Feb 02, 2022	BUY	$20.24 - $36.01 $22,264 - $39,611	1,100 Added 2.66%	42,400 $863,000
Q1 2021 Apr 28, 2021	BUY	$29.24 - $42.03 $731,000 - $1.05 Million	25,000 Added 153.37%	41,300 $1.36 Million
Q4 2020 Mar 12, 2021	SELL	$35.35 - $50.67 $28,280 - $40,536	-800 Reduced 4.68%	16,300 $589,000
Q3 2020 Oct 29, 2020	BUY	$35.98 - $47.66 $615,258 - $814,985	17,100 New	17,100 $607,000
Q4 2019 Feb 04, 2020	SELL	$37.13 - $74.62 $375,013 - $753,662	-10,100 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$39.36 - $76.8 $397,536 - $775,680	-10,100 Reduced 50.0%	10,100 $399,000
Q2 2019 Aug 01, 2019	BUY	$52.76 - $82.19 $416,804 - $649,301	7,900 Added 64.23%	20,200 $1.52 Million
Q1 2019 May 10, 2019	BUY	$27.39 - $68.41 $60,258 - $150,502	2,200 Added 21.78%	12,300 $520,000
Q4 2018 Feb 12, 2019	SELL	$22.8 - $33.93 $50,160 - $74,646	-2,200 Reduced 17.89%	10,100 $261,000
Q3 2018 Nov 09, 2018	SELL	$29.75 - $43.08 $8,925 - $12,924	-300 Reduced 2.38%	12,300 $0
Q1 2018 May 03, 2018	BUY	$17.1 - $26.61 $215,460 - $335,286	12,600 New	12,600 $299,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.